nmCRPC VL

STAMPEDE Analysis of Abiraterone With or Without Enzalutamide Added to Androgen Deprivation Therapy Compared to ADT Alone In High-Risk Non-Metastatic Prostate Cancer Patients– Gerhardt Attard

Details
Gerhardt Attard joins Alicia Morgans to discuss a combined analysis from two comparisons in the STAMPEDE platform. Dr. Gerhardt Attard presented a combined analysis from the STAMPEDE platform assessing the role of abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0...

Delayed Deterioration in Patient Quality of Life, the Impact of Darolutamide on Local Symptoms in the ARAMIS Trial – Neal Shore

Details
Alicia Morgans is joined by Neal Shore to discuss his presentation from the 2021 American Urologic Association (AUA) annual meeting on the relationship between PSA response and urinary and bowel adverse events (AEs), time to deterioration in the quality of life, and prostate cancer related invasive procedures in the ARAMIS trial. The authors examined the proportion of darolutamide patients achievi...

Overall Survival Data from the Global, Phase 3 ARAMIS Trial in Men with Non Metastatic Castration-Resistant Prostate Cancer (nmCRPC) - Karim Fizazi

Details
Importance of early intervention in nmCRPC—A discussion with Karim Fizazi, MD, PhD. Darolutamide, an androgen receptor inhibitor, was developed to improve the safety profile of apalutamide and enzalutamide. It has a distinct structure that offers low penetration of the blood-brain barrier as well as other characteristics with the potential for fewer and less toxic adverse events (AEs). The primary...

Predictors of Survival, Healthcare Resource Utilization, and Healthcare Costs in Veterans with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) - Stephen Freedland

Details
In this discussion, Stephen Freedland, MD, joins Alicia Morgans, MD, MPH, to discuss a health economics study that was recently published titled, Predictors of survival, healthcare resource utilization, and healthcare costs in veterans with non-metastatic castration-resistant prostate cancer. The objective of this study was to evaluate the association of prostate-specific antigen doubling time (PS...

Significantly Longer Metastasis-Free Survival and Overall Survival in the ARAMIS Trial, Nonmetastatic Castration-Resistant Prostate Cancer - Christopher Wallis & Zachary Klaassen

Details
In this Journal Club, Christopher Wallis and Zachary Klaassen discuss the updated analysis in the most recent publication of the ARAMIS trial. In this publication, overall survival (OS) and all other secondary endpoints were evaluated. The ARAMIS trial looked at the use of darolutamide for delaying metastasis and death in men with nonmetastatic, castration-resistant prostate cancer. Drs. Wallis an...

ARAMIS Trial Demonstrates Significant Improvement in Overall Survival in nmCRPC - Neal Shore

Details
Following a presentation at the ASCO 2020 Annual Meeting, Neal Shore discusses the results of the phase III ARAMIS trial which randomized over 1,500 patients with non-metastatic castration-resistant prostate cancer to 600 mg of darolutamide orally twice daily with ADT, versus a placebo-controlled combination with ADT. The study had a composite endpoint of overall survival and radiographic progress...

The PROSPER Trial: Enzalutamide Demonstrates Significant Improvement in Overall Survival in Nonmetastatic Castration-Resistant Prostate Cancer - Cora Sternberg

Details
Cora Sternberg, MD, FACP, shares the final analysis of the PROSPER trial assessing enzalutamide for nonmetastatic castration-resistant prostate cancer (nmCRPC). In this double-blind, phase 3 trial, men with nonmetastatic, castration-resistant prostate cancer (defined on the basis of conventional imaging and a PSA doubling time of ≤10 months) who were continuing to receive androgen-deprivation ther...

Overall Survival Results of Phase III ARAMIS Study of Darolutamide Added to ADT for Non-metastatic Castration-Resistant Prostate Cancer (nmCRPC) - Karim Fizazi

Details
Darolutamide is a structurally unique androgen-receptor antagonist that is approved for the treatment of prostate cancer. ARAMIS is a randomized, double-blind, placebo-controlled, phase 3 trial involving men with nonmetastatic, castration-resistant prostate cancer, and a prostate-specific antigen doubling time of 10 months or less. Patients were randomly assigned in a 2:1 ratio to receive daroluta...

ARAMIS Trial: Darolutamide Demonstrates Improved Overall Survival in Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC) - Fred Saad

Details
Fred Saad provides his perspective on the newest ARAMIS trial results, presented at ASCO 2020. Results from the phase III androgen receptor inhibiting agent for metastatic-free survival (ARAMIS) trial that investigated darolutamide in men with non-metastatic castration-resistant prostate cancer (nmCRPC) showed a significant improvement in delaying the time to death in patients receiving darolutami...

Treatment Advances in Non-Metastatic Castration-Resistant Prostate Cancer - Evan Yu

Details
Evan Yu joins Alicia Morgans to discuss treatment advances in the non-metastatic castration-resistant prostate cancer space, focusing on the data and clinical implications of the ARAMIS trial. Biographies: Evan Yu, MD, Medical oncologist, treats prostate, bladder, and testicular cancer, and is passionate about providing a personalized medical approach to a selection of novel therapies, as well as...